金陵药业股份有限公司 2021 年第三季度报告 证券代码：000919 证券简称：金陵药业 公告编号：2021-056 金陵药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 √ 适用 □ 不适用 1 金陵药业股份有限公司 2021 年第三季度报告 单位：元 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 688,791,918. ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,422,221,213.81, representing a 24.41% increase compared to CNY 1,143,200,873.29 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached CNY 75,957,082.73, a significant increase of 211.64% from CNY 24,373,296.85 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 85,326,124.05, up 64.68% from CNY 51,812,897.76 year-on-year[22]. - The net cash flow from operating activities was CNY 164,927,320.35, showing a remarkable increase of 310.15% compared to CNY 40,211,934.86 in the same period last year[22]. - The basic earnings per share for the first half of 2021 was CNY 0.1507, which is a 211.36% increase from CNY 0.0484 in the previous year[22]. - The total operating revenue for the first half of 2021 was CNY 1,422,221,213.81, an increase of 24.4% compared to CNY 1,143,200,873.29 in the first half of 2020[138]. - The total operating costs for the first half of 2021 were CNY 1,295,044,203.65, up from CNY 1,064,977,269.47 in the same period last year, reflecting a growth of 21.6%[138]. - The net profit attributable to the parent company for the first half of 2021 was CNY 127,177,010.16, compared to CNY 78,223,603.82 in the first half of 2020, representing an increase of 62.5%[138]. - The company's total profit for the first half of 2021 was CNY 121,495,799.91, compared to CNY 48,070,775.75 in the previous year, marking an increase of 152.5%[143]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 4,421,670,305.33, reflecting a 3.22% increase from CNY 4,283,570,372.62 at the end of the previous year[22]. - The total liabilities increased to CNY 946,211,128.38 as of June 30, 2021, compared to CNY 850,425,124.64 at the end of 2020, marking an increase of 11.3%[133]. - The company's total assets as of June 30, 2021, amounted to CNY 4,421,670,305.33, up from CNY 4,283,570,372.62 at the end of 2020[133]. - The company's cash and cash equivalents decreased by 6.35% to CNY 1,077.62 million, down from CNY 1,315.72 million at the end of the previous year[54]. - The company's long-term equity investments were valued at 267,461,814.12 yuan, slightly up from 266,808,210.54 yuan[131]. Research and Development - In the first half of 2021, the company invested CNY 22.71 million in research and development, with a focus on advancing projects through the registration process[41]. - Research and development investment increased by 15.90% to CNY 22,707,636.56 compared to CNY 19,592,299.58 in the previous year[46]. - The company's R&D expenses for the first half of 2021 were CNY 22,707,636.56, compared to CNY 19,592,299.58 in the same period last year, reflecting an increase of 10.8%[138]. - The company has submitted 15 projects for the 2021 National Natural Science Foundation, indicating a strong commitment to scientific research[41]. Market and Industry Position - The company operates in a favorable industry environment, with the domestic pharmaceutical industry experiencing rapid growth driven by an aging population and increased health awareness[33]. - The company is positioned well within the industry, benefiting from a large population base and ongoing healthcare reforms in China[34]. - The company aims to strengthen its dual-platform development in pharmaceuticals and healthcare, leveraging national policies to enhance market positioning[36]. - The company has set a strategic direction for the "14th Five-Year Plan," focusing on innovation-driven development and enhancing efficiency through scale[36]. - The company has actively engaged in market research and developed marketing strategies to maintain its competitive edge in the blood supplement sector[38]. Risks and Challenges - The company faces risks including industry policy changes, operational risks due to the COVID-19 pandemic, and market competition risks[6]. - The company faces risks from industry policy changes, including drug approval and price control measures, which could significantly impact future development[65]. - The ongoing global pandemic poses operational risks, with potential adverse effects on company performance if the situation does not improve[66]. - Fluctuations in raw material prices could increase procurement costs, potentially squeezing profit margins and affecting overall performance[66]. Environmental and Social Responsibility - The company has established a strict quality control system, with no major product quality incidents reported to date, but remains vigilant against potential risks[67]. - Environmental protection compliance is critical, with the company classified as a key pollutant discharge unit, necessitating adherence to stringent regulations[76]. - The company has implemented a "rainwater and sewage diversion" system to manage wastewater effectively, ensuring compliance with environmental standards[77]. - The company has invested RMB 115,000 in social responsibility initiatives, focusing on health, education, and industry support[81]. - In health poverty alleviation, the company provided free clinical guidance and training to local healthcare workers, enhancing medical management[81]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The total number of shares outstanding remained at 504 million, with a slight adjustment in the structure due to management changes[113]. - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 45.23% of the shares, totaling 227,943,839 shares[115]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[88]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 10% to 15%[183]. - New product launches are expected to contribute an additional 5% to revenue growth in the upcoming quarters[183]. - The company is focusing on market expansion, targeting a 30% increase in market share in the next fiscal year[183]. - The company plans to continue expanding its market presence and investing in new product development[155].

金陵药业股份有限公司 2021 年第一季度报告全文 金陵药业股份有限公司 2021 年第一季度报告 2021-029 2021 年 04 月 1 金陵药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁玉堂、主管会计工作负责人陈亚军及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 701,603,298.78 | 513,804,171.32 | 36.55% | | 归属于上市公司股东的净利润（元） | 34,999,569.83 | -27,613 ...

Financial Performance - The company reported a total revenue of 504 million CNY for the year 2020, with a year-on-year growth of 10%[6] - The company's operating revenue for 2020 was ¥2,503,732,374.15, a decrease of 1.23% compared to ¥2,534,920,539.72 in 2019[6] - The net profit attributable to shareholders was ¥65,136,495.93, representing a significant decline of 55.18% from ¥145,319,439.10 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥85,427,396.25, an increase of 102.30% compared to ¥42,228,340.42 in 2019[6] - The net cash flow from operating activities decreased by 33.14% to ¥311,464,432.11 from ¥465,847,095.18 in 2019[6] - The total assets at the end of 2020 were ¥4,283,570,372.62, reflecting a 3.01% increase from ¥4,158,340,176.15 at the end of 2019[6] - The company reported a weighted average return on equity of 2.26%, down from 5.08% in 2019, indicating a decline in profitability[6] - The company achieved total operating revenue of 250,373.24 million yuan and a net profit attributable to shareholders of 6,513.65 million yuan during the reporting period[37] - Total revenue for 2020 was ¥2,503,732,374.15, a decrease of 1.23% compared to ¥2,534,920,539.72 in 2019[47] - Revenue from pharmaceutical production and sales was ¥1,345,378,717.03, accounting for 53.73% of total revenue, down 1.89% from the previous year[47] - Revenue from medical services was ¥1,123,082,965.40, representing 44.86% of total revenue, a decrease of 1.27% year-over-year[47] Dividend and Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 1 CNY per 10 shares, totaling 50.4 million CNY[6] - In 2020, the company proposed a cash dividend of CNY 1.00 per share, totaling CNY 50,400,000, which represents 77.38% of the distributable profit[89][92] - The company's net profit for 2020 was CNY 46,366,647.92, with a distributable profit of CNY 785,313,845.82 at year-end[92] Market and Business Strategy - The company plans to continue expanding its market presence and invest in new product development to enhance its competitive edge[6] - The company is focused on expanding its pharmaceutical and healthcare service platforms to adapt to changing market conditions[37] - The company launched new products such as "Yihua" series honeysuckle tea and Dendrobium flower tea, laying a foundation for expanding the health product line[40] - The company is currently advancing several R&D projects, including the development of new drugs and improvements to existing products[59] - The company plans to focus on the "14th Five-Year Plan" strategy, emphasizing the dual-platform strategy of "pharmaceuticals and health care" for deeper integration[82] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential deals[166] Operational Challenges and Compliance - The company emphasized the importance of maintaining compliance with industry regulations and managing risks related to market competition and raw material price fluctuations[6] - The company did not report any significant changes in its business, management, or operational models compared to the previous year[29] - The company has not reported any changes in its main business operations or major shareholders during the reporting period[18] - The company has not engaged in any significant equity investments during the reporting period[74] - The company has not reported any significant changes in its financial indicators due to the share changes[141] Research and Development - Research and development expenses for the year were ¥43,709,428.30, a slight decrease of 0.47% compared to ¥43,915,066.29 in 2019[59] - The proportion of R&D expenses to operating income increased to 1.75% from 1.73% in the previous year[62] - The company has made significant progress in its consistency evaluation projects, with major milestones achieved during the reporting period[61] - The company is investing 50 million yuan in R&D for new technologies aimed at improving production efficiency[166] Social Responsibility and Community Engagement - The company invested a total of 719,400 CNY in poverty alleviation efforts, including 42,000 CNY for industrial development projects and 46,000 CNY for educational support[128] - The company supported 99 impoverished students with a total funding of 46,000 CNY in 2020, continuing its commitment to educational assistance[128] - The company provided 42,000 CNY for health poverty alleviation, including support for local healthcare facilities and free medical services[128] - The company has been recognized for its contributions to social responsibility, including awards for blood donation efforts[128] - The company plans to continue its poverty alleviation initiatives in 2021, focusing on community engagement and healthcare support[130] Governance and Management - The company has undergone a change in its board of directors and senior management during the reporting period[134] - The company has a total of 9 board members, with 5 currently in office and 4 independent directors[155] - The average age of the current board members is approximately 50 years[155] - The company has a diverse management team with backgrounds in economics, pharmacy, and engineering, enhancing its operational capabilities[161] - The company is focused on maintaining stability in its leadership and shareholding structure[156] - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring compliance with tax regulations[188] Shareholder Information - The company reported a total share count of 504,000,000, with 99.75% being unrestricted shares and 0.25% being restricted shares[139] - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., holds 45.23% of the shares, totaling 227,943,839 shares[142] - The actual controller of the company is the Nanjing Municipal Government State-owned Assets Supervision and Administration Commission, which has not changed during the reporting period[147] - The total shares held by the board members at the end of the period increased to 1,019,736 shares, with an increase of 30,000 shares during the period[156] Environmental Compliance - The company has established two wastewater treatment systems with a daily processing capacity of 2,000 m³, ensuring compliance with environmental standards[131] - The company has implemented a comprehensive environmental monitoring program to ensure compliance with pollution discharge standards[132]

金陵药业股份有限公司 2020 年第三季度报告全文 金陵药业股份有限公司 2020 年第三季度报告 2020-047 2020 年 10 月 1 金陵药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁玉堂、主管会计工作负责人梁玉堂及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,188,614,207.05 | 4,158,340,176.15 | | 0.73% | | 归属于上市公司股东的净资产 | 2,869,928,095 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,143,200,873.29, a decrease of 11.32% compared to CNY 1,289,138,373.80 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 24,373,296.85, down 89.27% from CNY 227,209,633.68 in the previous year[19]. - The net cash flow from operating activities was CNY 40,211,934.86, representing an 83.13% decline from CNY 238,319,127.90 in the same period last year[19]. - Basic earnings per share decreased to CNY 0.0484, down 89.26% from CNY 0.4508 in the previous year[19]. - The company reported a decrease of 35.11% in net profit after deducting non-recurring gains and losses, totaling CNY 51,812,897.76 compared to CNY 79,848,875.68 in the previous year[19]. - The weighted average return on net assets was 0.84%, down 6.92% from 7.76% in the previous year[19]. - The company reported a total non-recurring loss of 27.44 million yuan during the reporting period[23]. - The company reported a significant loss of CNY 41,909,928.04 in fair value changes, reflecting market volatility[47]. - The company reported a significant decline in investment income, which fell to CNY 9,424,629.66 from CNY 22,043,317.27, a decrease of 57.3%[143]. - The total comprehensive income for the first half of 2020 decreased by CNY 3,792,051 compared to the previous period[162]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,169,510,893.50, a slight increase of 0.27% from CNY 4,158,340,176.15 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 2.13% to CNY 2,816,699,968.21 from CNY 2,878,006,671.36 at the end of the previous year[19]. - Cash and cash equivalents at the end of the reporting period were CNY 1,056,543,603.43, representing 25.34% of total assets, an increase of 4.69% from the previous year[49]. - The company's inventory at the end of the reporting period was CNY 222,978,692.20, slightly up from CNY 218,026,028.78, maintaining a stable proportion of total assets[49]. - The total liabilities increased to CNY 791,908,773.34 from CNY 733,622,631.91, representing a rise of approximately 7.93%[135]. - The company's total liabilities at the end of the first half of 2020 were CNY 1,477,971,000, reflecting a decrease from CNY 1,588,000,000 in the previous period[164]. Revenue Sources - Revenue from pharmaceutical production and sales was CNY 631,851,022.86, accounting for 55.27% of total revenue, down 8.26% year-on-year[43]. - Revenue from medical services was CNY 496,322,888.47, representing 43.42% of total revenue, a decline of 15.18% compared to the previous year[43]. - The gross profit margin for pharmaceutical production and sales was 27.87%, down 2.83% from the previous year[45]. Investment and R&D - Research and development investment increased by 17.22%, totaling ¥19,592,299.58 compared to ¥16,714,202.98 in the previous year[41]. - The company plans to cultivate 1-2 new municipal key specialties based on existing key specialties in Yangzhou[36]. - The company has entered the registration process for several new drug projects, including "Milrinone Raw Material" and "Docetaxel Injection" which are currently under review[38]. Risks and Challenges - The company faces risks including industry policy changes, uncertainties due to the COVID-19 pandemic, and market competition[5]. - The COVID-19 pandemic has created uncertainties that could significantly affect the company's performance if the situation worsens[66]. - The company faces significant market competition risks due to increasing industry concentration, which may impact its competitive advantage and profitability[68]. - Fluctuations in raw material prices pose a risk to the company's procurement costs, potentially squeezing profit margins[68]. Corporate Governance and Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,726[114]. - The largest shareholder, Nanjing New Industry Investment Group, holds 227,943,839 shares, representing 45.23% of the total shares[115]. - The company has not experienced any major litigation or arbitration matters during the reporting period[81]. - The company has not conducted any asset or equity acquisitions or sales during the reporting period[88]. Environmental and Social Responsibility - The company has established a comprehensive emergency response plan for environmental incidents, updated in January 2019[102]. - The company actively participated in COVID-19 response efforts, sending 7 medical staff to support Hubei province[104]. - The company contributed RMB 231,000 in funds for poverty alleviation efforts in the first half of 2020[105]. - A total of 17 students received financial assistance amounting to RMB 90,000 as part of the education poverty alleviation initiative[106]. Financial Reporting and Compliance - The half-year financial report has not been audited[79]. - The financial statements prepared by the company comply with the requirements of the accounting standards, reflecting its financial position and operating results accurately[178]. - The company has implemented accounting policy changes that may affect future financial reporting and performance metrics[157].

金陵药业股份有限公司 2020 年第一季度报告全文 金陵药业股份有限公司 2020 年第一季度报告 2020-018 2020 年 04 月 1 金陵药业股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁玉堂、主管会计工作负责人梁玉堂及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 513,804,171.32 | 613,306,096.90 | -16.22% | | 归属于上市公司股东的净利润（元） | -27,613,261.60 | 210,3 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.7 CNY per 10 shares based on a total of 504 million shares, with no stock bonus[4] - The company plans to distribute a cash dividend of 1.70 yuan per 10 shares, totaling 85,680,000 yuan, which represents 58.96% of the distributable profit[94] - The company has maintained a consistent cash dividend policy over the past three years, with the same dividend amount proposed for 2019 as in previous years[92] - The company's net profit for 2019 was CNY 144,040,746.20, with a distributable profit of CNY 129,636,671.58 after statutory surplus reserve allocation[95] - The total cash dividend distributed was CNY 85,680,000.00, resulting in a remaining undistributed profit of CNY 743,583,862.69 at the end of 2019[95] Financial Performance - The company's operating revenue for 2019 was ¥2,534,920,539.72, a decrease of 12.56% compared to ¥2,899,079,022.11 in 2018[6] - The net profit attributable to shareholders was ¥145,319,439.10, down 39.90% from ¥241,786,876.83 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥42,228,340.42, a decline of 65.91% from ¥123,856,759.61 in 2018[6] - The total assets at the end of 2019 were ¥4,158,340,176.15, reflecting a growth of 7.04% compared to ¥3,884,935,435.88 at the end of 2018[6] - The company's weighted average return on equity decreased to 5.08% from 9.05% in 2018, a drop of 3.97%[6] Research and Development - The company reported a significant focus on R&D for new products and technologies, aiming to enhance its market position[12] - The company has established a technical center to support its R&D efforts and improve product quality[10] - The company's research and development expenditure for the period was ¥43,915,066.29, contributing to the enhancement of its R&D capabilities and core competitiveness[58] - R&D investment increased by 28.70% to ¥43,915,066.29, representing 1.73% of operating revenue, up from 1.18%[59] - The company is focused on enhancing quality standards and technical innovation through joint laboratories and postdoctoral workstations[41] Market Expansion and Strategy - The company is actively pursuing market expansion strategies to increase its market share in the pharmaceutical industry[12] - The company plans to shift its sales model from traditional marketing to professional academic and precision marketing to improve efficiency and market share[40] - The company aims to strengthen its presence in the healthcare sector by creating integrated medical and elderly care systems[40] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for this purpose[186] - Market expansion efforts are underway, targeting a 25% increase in market share in the next fiscal year[186] Compliance and Risk Management - The company acknowledges risks related to industry policy changes, product bidding failures, price declines, and market competition[4] - The company emphasizes the importance of compliance with the Good Manufacturing Practice (GMP) standards in its production processes[10] - The company is monitoring raw material prices closely and has implemented measures to optimize procurement processes to mitigate cost pressures[85] - The company faces risks related to industry policy changes, including stricter regulations and cost control measures in the healthcare sector[82] - The company has established a strict quality control system, ensuring no major quality incidents have occurred to date[85] Corporate Governance - The company has not reported any changes in its controlling shareholders since its establishment[16] - The actual controller and related parties fulfilled their commitments during the reporting period[96] - The company has committed to strict adherence to existing competition resolution agreements, with accountability for any violations[101] - The company maintains independent operations from its controlling shareholder, ensuring no harm to the rights of other shareholders[197] - The company's senior management, including the chairman and president, do not hold positions in the controlling shareholder or its other enterprises, ensuring personnel independence[200] Social Responsibility and Environmental Management - The company has actively engaged in social responsibility initiatives, including support for local communities and environmental protection efforts[139] - The company has committed 415,000 yuan in poverty alleviation funds in 2019, focusing on health, education, and targeted poverty alleviation efforts[143] - The company has established a comprehensive quality assurance system to ensure the safety and quality of its pharmaceutical products[140] - The company has received approval for its environmental impact assessment and complies with pollution discharge standards[151] - The company is increasing investments in environmental management to comply with stricter regulations and mitigate potential environmental risks[86] Employee and Management Structure - The company employed a total of 4,767 staff, including 959 in the parent company and 3,808 in major subsidiaries[191] - The total annual compensation for 19 directors, supervisors, and senior management personnel was 6.91 million yuan (pre-tax) during the reporting period[188] - The company emphasizes employee training and development, implementing various training programs to enhance overall employee quality[193] - The company has maintained a stable leadership team, with most members having served since at least 2014, ensuring continuity in strategic direction[179] - The professional composition of employees includes 494 production personnel, 111 sales personnel, and 3,113 technical personnel[191] Financial Management - The company has not utilized any fundraising during the reporting period, indicating a self-sustained financial approach[77] - The company has no derivative investments, reflecting a conservative investment strategy during the reporting period[76] - The company reported a related party transaction amounting to CNY 18,746.47 million with Nanjing Yitong Pharmaceutical Co., Ltd., exceeding the estimated amount of CNY 16,500 million[127] - The company has invested 56.85 million yuan in bank wealth management products, with an outstanding balance of 9.8 million yuan[137] - The company has not reported any significant contracts or guarantees during the reporting period[135][138]

金陵药业股份有限公司 2019 年第三季度报告全文 金陵药业股份有限公司 2019 年第三季度报告 2019-042 2019 年 10 月 1 金陵药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,226,266,961.13 | 3,884,935,435.88 | | 8.79% | | 归属于上市公司股东的净资产 | 2,966,421,511.64 | 2,736,819,527.33 | | 8.39% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | | | 增减 | | 年同期增减 | | 营业收入（元） | 650,836,228.49 | ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,289,138,373.80, a decrease of 17.62% compared to CNY 1,564,930,564.75 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 227,209,633.68, representing a significant increase of 154.06% from CNY 89,430,082.55 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was CNY 79,848,875.68, down 11.83% from CNY 90,563,383.82 in the previous year[18]. - The basic earnings per share increased to CNY 0.4508, up 154.11% from CNY 0.1774 in the same period last year[18]. - The total assets at the end of the reporting period were CNY 4,258,064,604.53, an increase of 9.60% compared to CNY 3,884,935,435.88 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were CNY 2,957,255,332.68, reflecting an increase of 8.05% from CNY 2,736,819,527.33 at the end of the previous year[18]. - The net cash flow from operating activities was CNY 238,319,127.90, a decrease of 10.58% from CNY 266,531,405.65 in the same period last year[18]. - The company achieved total operating revenue of CNY 1,289.14 million and a net profit attributable to shareholders of CNY 227.21 million during the reporting period[31]. Investment and Assets - Long-term equity investments increased by 239.79% compared to the end of the previous year, primarily due to increased investments in new projects[29]. - The company’s total assets related to trading financial assets increased by CNY 25,633,316.22, attributed to adjustments made under the newly revised financial instrument accounting standards[29]. - The total investment during the reporting period was ¥180 million, a significant increase of 103.02% compared to ¥88.66 million in the same period last year[52]. - The company is currently constructing a new emergency and inpatient building at Suqian Hospital, with a total investment of ¥16.92 million, which is 35% of the planned investment[56]. - The total investment in securities amounted to 135,644 million RMB, with a fair value of 163,279 million RMB at the end of the reporting period[57]. Revenue Segments - The sales volume of the key product, Su Li Fei (琥珀酸亚铁片), continued to grow steadily, while the sales volume of another key product, Mai Luo Ning injection (脉络宁注射液), saw a slowdown in decline[27]. - The medical services segment saw a revenue increase of 9.95% to RMB 585,136,324.22, although the gross margin decreased by 6.86% to 18.75%[42]. - Revenue from traditional Chinese medicine reached ¥189.31 million, representing a 21.50% increase year-over-year, but a 22.92% decrease compared to the previous period[43]. - Chemical drug revenue was ¥499.41 million, showing a 34.20% increase year-over-year, but a significant decline of 33.66% compared to the previous period[43]. - Medical services revenue amounted to ¥585.14 million, an 18.75% increase year-over-year, with a 9.95% increase compared to the previous period[43]. Risks and Challenges - The company faces risks including industry policy changes, market competition, and raw material price fluctuations[4]. - The company faced risks from industry policy changes due to ongoing healthcare reforms, which may impact operational strategies[63]. - The company faces risks from fluctuations in raw material prices, which could significantly impact procurement costs and profit margins[64]. - There is a risk of goodwill impairment due to fluctuations in the operating conditions of acquired companies, which could adversely affect the company's financial performance[64]. Research and Development - Research and development investment amounted to RMB 16,714,202.98, down 19.77% from the previous year, indicating a potential shift in focus or resource allocation[40]. - The company is committed to enhancing its technological innovation capabilities through joint laboratories and research projects, aiming to accelerate the development of innovative drugs[35]. - The company plans to enhance product quality and R&D capabilities to maintain competitive advantages amid increasing market competition[63]. - The company is focused on improving R&D capabilities and optimizing project selection to minimize risks associated with drug development and consistency evaluation[65]. Corporate Governance and Compliance - The company has made commitments regarding the management of related party transactions and competition to protect its interests[72]. - The company has not experienced any major litigation or arbitration matters during the reporting period[79]. - The company has not engaged in any significant contracts or leasing arrangements during the reporting period[88]. - The company has established specific accounting policies and estimates based on its operational characteristics, particularly regarding revenue recognition[173]. Social Responsibility - In the first half of 2019, the company invested a total of 3.39 million RMB in poverty alleviation efforts[99]. - The company provided financial assistance to 19 impoverished students, with a total investment of 0.39 million RMB for education support[100]. - The company donated over 30,000 RMB to support the construction of a beautiful village and aid for impoverished residents in Mengbei Village, Xigang Street, Qixia District, Nanjing[98]. - The company has actively engaged in health and education poverty alleviation initiatives, including free medical services and volunteer activities[98]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,146[110]. - The largest shareholder, Nanjing New Industry Investment Group, holds 45.23% of the shares, totaling 227,943,839 shares[110]. - The second-largest shareholder, Fuzhou Investment Management Co., holds 4.94% with 24,920,000 shares[110]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[112]. Environmental Compliance - The company has established two wastewater treatment systems with a daily processing capacity of 1,200 m³ and 800 m³, which are operating normally[94]. - The company has received approval for its environmental impact assessment and has obtained the necessary pollution discharge permits[95]. - The company is committed to increasing investment in environmental protection management to comply with stricter regulations and mitigate potential impacts on operating profits[66].